BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:IMX Colloquium - Brain-targeted drug delivery systems and AI-gener
 ated synthetic biology medications
DTSTART:20250331T131500
DTEND:20250331T141500
DTSTAMP:20260921T183918Z
UID:4b2ff6b071351382a5a11acc2eae01ed135c8140aa7ef0a4d3eb91be
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Avi Schroeder\, Technion\, Israel\nNanotechnology holds 
 numerous potential benefits for treating disease\, including the ability t
 o transport complex molecular cargoes\, including RNA and proteins\, as we
 ll as targeting specific tissues\, including the brain. Brain-targeted nan
 oparticles enhance the delivery of monoclonal antibodies (mAbs) across the
  blood-brain-barrier (BBB) and into neurons\, thereby allowing the intrace
 llular and extracellular treatment of Parkinson’s disease. 100-nm BTL cr
 oss human BBB models intact and are taken up by primary neurons. Within ne
 urons\, SynO4 is released from the nanoparticles and bound to its target -
  alpha-synuclein (AS)\, thereby reducing AS aggregation\, and enhancing ne
 uronal viability. In vivo\, intravenous administration results in a seven-
 fold increase in mAbs in brain cells\, decreasing AS aggregation and neuro
 inflammation and improving behavioral motor function and learning ability 
 in mice. Targeted nanotechnologies offer a valuable platform for drug deli
 very to treat brain neurodegeneration. The evolution of drug delivery syst
 ems into synthetic cells\, programmed nanoparticles with an autonomous syn
 -bio capacity to synthesize diagnostic and therapeutic proteins inside the
  body\, and their promise for treating disease\, will be discussed.\n\nBio
 : Avi Schroeder is a Professor of Chemical Engineering at the Technion–I
 srael Institute of Technology\, where he heads the Laboratory for Targeted
  Drug Delivery and Personalized Medicine Technologies (https://www.schroed
 erlab.com/).\nDr. Schroeder conducted his Postdoctoral studies at the Mass
 achusetts Institute of Technology (MIT)\, and his PhD jointly at the Hebre
 w and Ben Gurion Universities.\nAvi is the recipient of more than 40 natio
 nal and international recognitions including being named a Fellow of the R
 oyal Society of Chemistry\, KAVLI Fellow\, awarded the Intel Nanotechnolog
 y-\, TEVA Pharmaceuticals-\, and the Wolf Foundation Krill Awards. Avi is 
 the author of more than 60 papers\, the inventor of 19 patents\, and co-fo
 under of multiple startup companies based on these discoveries. Schroeder 
 is a former member of the Israel Young National Academy of Sciences\, is a
  current member of Israel’s National Council for Civilian Research and D
 evelopment\, and the President of the Controlled Release Society (CRS).
LOCATION:MXF 1 https://plan.epfl.ch/?room==MXF%201
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR